 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 January 1998 | Volume 128 Issue 2 | Pages 89-95
Background: Stroke is a leading cause of death in the industrialized world, and hypercholesterolemia may be a risk factor for stroke.
Objective: To determine whether reducing cholesterol levels with HMGcoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors or other antilipidemic interventions reduces risk for nonfatal and fatal stroke.
Data Sources: A systematic search in the MEDLINE and EMBASE databases of the English-language and non-English-language literature published from 1966 through October 1996.
Study Selection: All randomized, controlled trials of any cholesterol-lowering intervention that reported data on nonfatal and fatal strokes, on death from coronary heart disease, and on overall mortality were included. Whether treatment effects differed according to the type of cholesterol-lowering intervention used was investigated.
Data Extraction: Trials were reviewed for methods, inclusion and exclusion criteria, and outcomes.
Data Synthesis: 28 trials (for a total of 49 477 study participants in the intervention group and 56 636 participants in the control group) were included. The risk ratio for nonfatal and fatal stroke with HMGcoA reductase inhibitors was 0.76 (95% CI, 0.62 to 0.92; test of heterogeneity, P > 0.2). The risk ratios for nonfatal and fatal stroke with fibrates, resins, and dietary interventions were all close to 1.0, and the difference between the HMGcoA reductase inhibitor effect and the pooled estimate for all other interventions would, under the null hypothesis, be unlikely to occur by chance (P = 0.01). Trials with HMGcoA reductase inhibitors also showed reductions in rates of death from coronary heart disease and overall mortality.
Conclusion: This meta-analysis of randomized, controlled trials suggests that in hyperlipidemic patients who have not previously had stroke, HMGcoA reductase inhibitors reduce the incidence of stroke.
Author and Article Information
From Kantonsspital Basel, Basel, Switzerland; and McMaster University, Hamilton, Ontario, Canada.
ARTICLE
Effect of HMGcoA Reductase Inhibitors on Stroke
A Meta-Analysis of Randomized, Controlled Trials
Grant Support: In part by grant 32-38793.930 from the Swiss National Research Foundation.
Requests for Reprints: Heiner C. Bucher, MD, Medizinische Universitats-Poliklinik, Kantonsspital Basel, CH-4031 Basel, Switzerland.
Current Author Addresses: Dr. Bucher: Medizinische Universitats-Poliklinik, Kantonsspital Basel, CH-4031 Basel, Switzerland.
This article has been cited by other articles:
|
|
 |
|
  L. R. Caplan A 70-Year-Old Man With a Transient Ischemic Attack: Review of Internal Carotid Artery Stenosis JAMA, July 2, 2008; 300(1): 81 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, J. Dallongeville, G. De Backer, S. Ebrahim, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) Eur. Heart J., October 1, 2007; 28(19): 2375 - 2414. [Full Text] [PDF]
|
|
|
|
 |
|
 K. G. Shojania, M. Sampson, M. T. Ansari, J. Ji, S. Doucette, and D. Moher How Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis Ann Intern Med, August 21, 2007; 147(4): 224 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Khurana, H. R. Bejjanki, G. Caldito, and M. W. Owens Statins Reduce the Risk of Lung Cancer in Humans: A Large Case-Control Study of US Veterans Chest, May 1, 2007; 131(5): 1282 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Ward, C. W. Don, K. T. Furlong, and R. M. Lang Predictors of Long-Term Mortality in Patients With Ischemic Stroke Referred for Transesophageal Echocardiography Stroke, January 1, 2006; 37(1): 204 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Hansen, J. P. Hildebrand, E. E. Ferguson, and J. H. Stein Outcomes in 45 Patients With Statin-Associated Myopathy Arch Intern Med, December 12, 2005; 165(22): 2671 - 2676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Prepared by: British Cardiac Society, British Hype JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice Heart, December 1, 2005; 91(suppl_5): v1 - v52. [Full Text] [PDF]
|
|
|
|
|
|
B. A. Golomb, M. H. Criqui, H. White, and J. E. Dimsdale Conceptual Foundations of the UCSD Statin Study: A Randomized Controlled Trial Assessing the Impact of Statins on Cognition, Behavior, and Biochemistry Arch Intern Med, January 26, 2004; 164(2): 153 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Bowman, H. D. Sesso, J. Ma, T. Kurth, C. S. Kase, M. J. Stampfer, and J. M. Gaziano Cholesterol and the Risk of Ischemic Stroke Stroke, December 1, 2003; 34(12): 2930 - 2934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M R Law, N J Wald, and A R Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ, June 25, 2003; 326(7404): 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kaste Statins in Threatened Stroke Stroke, February 1, 2003; 34(2): 351 - 353. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sironi, M. Cimino, U. Guerrini, A. M. Calvio, B. Lodetti, M. Asdente, W. Balduini, R. Paoletti, and E. Tremoli Treatment With Statins After Induction of Focal Ischemia in Rats Reduces the Extent of Brain Damage Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 322 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. W. Chan, A. M. Oza, and L. L. Siu The Statins as Anticancer Agents Clin. Cancer Res., January 1, 2003; 9(1): 10 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Straus, S. R. Majumdar, and F. A. McAlister New Evidence for Stroke Prevention: Scientific Review JAMA, September 18, 2002; 288(11): 1388 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Benjamin, S. C. Smith Jr, R. S. Cooper, M. N. Hill, and R. V. Luepker Task Force #1--magnitude of the prevention problem: opportunities and challenges J. Am. Coll. Cardiol., August 21, 2002; 40(4): 588 - 603. [Full Text] [PDF]
|
|
|
|
|
|
G. J. Blake, P. M. Ridker, and K. M. Kuntz Projected life-expectancy gains with statin therapy for individuals with elevated c-reactive protein levels J. Am. Coll. Cardiol., July 3, 2002; 40(1): 49 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Chan, G. F. Watts, P. H. R. Barrett, L. J. Beilin, and T. A. Mori Effect of Atorvastatin and Fish Oil on Plasma High-Sensitivity C-Reactive Protein Concentrations in Individuals with Visceral Obesity Clin. Chem., June 1, 2002; 48(6): 877 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Koren-Morag, D. Tanne, E. Graff, U. Goldbourt, and for the Bezafibrate Infarction Prevention Study Gr Low- and High-Density Lipoprotein Cholesterol and Ischemic Cerebrovascular Disease: The Bezafibrate Infarction Prevention Registry Arch Intern Med, May 13, 2002; 162(9): 993 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Gorelick Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy: An Invited Review Stroke, March 1, 2002; 33(3): 862 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Rizos and D. P Mikhailidis Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? Cardiovasc Res, November 1, 2001; 52(2): 199 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bloomfield Rubins, J. Davenport, V. Babikian, L. M. Brass, D. Collins, L. Wexler, S. Wagner, V. Papademetriou, G. Rutan, and S. J. Robins Reduction in Stroke With Gemfibrozil in Men With Coronary Heart Disease and Low HDL Cholesterol : The Veterans Affairs HDL Intervention Trial (VA-HIT) Circulation, June 12, 2001; 103(23): 2828 - 2833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Brett, J. F. Meilof, B. M.I. Uitdehaag, O. Fruchter, H. D. White, R. J. Simes, A. M. Tonkin, and The LIPID Study Group Pravastatin Therapy and the Risk of Stroke N. Engl. J. Med., December 21, 2000; 343(25): 1894 - 1896. [Full Text]
|
|
|
|
|
|
J. Tuomilehto Controlling glucose and blood pressure in type 2 diabetes BMJ, August 12, 2000; 321(7258): 394 - 395. [Full Text]
|
|
|
|
|
|
H. D. White, R. J. Simes, N. E. Anderson, G. J. Hankey, J. D.G. Watson, D. Hunt, D. M. Colquhoun, P. Glasziou, S. MacMahon, A. C. Kirby, et al. Pravastatin Therapy and the Risk of Stroke N. Engl. J. Med., August 3, 2000; 343(5): 317 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J F Albucher, J Ferrieres, J B Ruidavets, B Guiraud-Chaumeil, B P Perret, and F Chollet Serum lipids in young patients with ischaemic stroke: a case-control study J. Neurol. Neurosurg. Psychiatry, July 1, 2000; 69(1): 29 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Tunick and I. Kronzon Atheromas of the thoracic aorta: clinical and therapeutic update J. Am. Coll. Cardiol., March 1, 2000; 35(3): 545 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Hess, A. M. Demchuk, L. M. Brass, and F. M. Yatsu HMG-CoA reductase inhibitors (statins): A promising approach to stroke prevention Neurology, February 22, 2000; 54(4): 790 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kato, T. Tamada, T. Nabika, K. Ueno, T. Gotoda, C. Matsumoto, T. Mashimo, M. Sawamura, K. Ikeda, Y. Nara, et al. Identification of Quantitative Trait Loci for Serum Cholesterol Levels in Stroke-Prone Spontaneously Hypertensive Rats Arterioscler. Thromb. Vasc. Biol., January 1, 2000; 20(1): 223 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Demchuk, D. C. Hess, L. M. Brass, and F. M. Yatsu Is Cholesterol a Risk Factor for Stroke?: Yes Arch Neurol, December 1, 1999; 56(12): 1518 - 1520. [Full Text] [PDF]
|
|
|
|
|
|
R. H. Knopp Drug Treatment of Lipid Disorders N. Engl. J. Med., August 12, 1999; 341(7): 498 - 511. [Full Text] [PDF]
|
|
|
|
|
|
G. J. Hankey Stroke: How Large a Public Health Problem, and How Can the Neurologist Help? Arch Neurol, June 1, 1999; 56(6): 748 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein, J. L. Saver, J. S. Elkins, P. G. Shekelle, R.E. Park, M. R. Chassin, R. B. Haynes, H. J.M. Barnett, D. W. Taylor, and J. V. Tu Carotid Endarterectomy N. Engl. J. Med., April 15, 1999; 340(15): 1209 - 1212. [Full Text]
|
|
|
|
|
|
P. B. Gorelick, R. L. Sacco, D. B. Smith, M. Alberts, L. Mustone-Alexander, D. Rader, J. L. Ross, E. Raps, M. N. Ozer, L. M. Brass, et al. Prevention of a First Stroke: A Review of Guidelines and a Multidisciplinary Consensus Statement From the National Stroke Association JAMA, March 24, 1999; 281(12): 1112 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Plehn, B. R. Davis, F. M. Sacks, J. L. Rouleau, M. A. Pfeffer, V. Bernstein, T. E. Cuddy, L. A. Moye, L. B. Piller, J. Rutherford, et al. Reduction of Stroke Incidence After Myocardial Infarction With Pravastatin : The Cholesterol and Recurrent Events (CARE) Study Circulation, January 19, 1999; 99(2): 216 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A Papadakis, D. P Mikhailidis, and A. F Winder Lipids and stroke: neglect of a useful preventive measure? Cardiovasc Res, November 1, 1998; 40(2): 265 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 HMGcoA REDUCTASE INHIBITORS PREVENT STROKE Journal Watch (General), January 23, 1998; 1998(123): 2 - 2. [Full Text]
|
|
Article
